- Open Access
NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe
© Hegele et al; licensee BioMed Central Ltd. 2005
- Received: 25 July 2005
- Accepted: 12 August 2005
- Published: 12 August 2005
NPC1L1 encodes a putative intestinal sterol transporter which is the likely target for ezetimibe, a new type of lipid-lowering medication. We previously reported rare non-synonymous mutations in NPC1L1 in an individual who had no plasma lipoprotein response to ezetimibe. We next hypothesized that common variants in NPC1L1 would underlie less extreme inter-individual variations in the plasma LDL cholesterol response to ezetimibe.
In 101 dyslipidemic subjects, we found that NPC1L1 haplotype was significantly associated with inter-individual variation in the response of plasma LDL cholesterol to treatment with ezetimibe for 12 weeks. Specifically, about one subject in eight lacked the common NPC1L1 haplotype 1735C-25342A-27677T and these subjects had a significantly greater reduction in plasma LDL cholesterol with ezetimibe than subjects with at least one copy of this haplotype (-35.9+4.0 versus -23.6+1.6 percent reduction, P = 0.0054). This was paralleled by a similar non-significant trend of between-haplotype difference in reduction of total cholesterol.
These preliminary pharmacogenetic results suggest that NPC1L1 variation is associated with inter-individual variation in response to ezetimibe treatment.
- Pairwise Linkage Disequilibrium
- Shrimp Alkaline Phosphatase
- Ezetimibe Treatment
Ezetimibe, the first member of a new class of medications, primarily reduces plasma concentration of low-density lipoprotein (LDL) cholesterol by blocking sterol absorption in enterocytes . Ezetimibe probably interferes with the normal function of the NPC1L1 gene product, which appears to govern sterol absorption in the small intestine [2–5]. The mean plasma LDL cholesterol reduction seen with ezetimibe is 20 to 25%, and this has been remarkably consistent across patient subgroups defined by age, gender, ethnic background and concomitant use of other lipid regulating agents, such as statin drugs [6–9]. But despite the concordance in mean reductions, there is a wide range of inter-individual variation in the LDL cholesterol response to ezetimibe. A possible genetic basis for this inter-individual variation was suggested by our previous observation of rare non-synonymous NPC1L1 mutations in a non-responder to ezetimibe . During the course of those studies, we identified several single nucleotide polymorphisms (SNPs) in NPC1L1 . These SNPs have enabled assessment of common genetic variation at NPC1L1, which we hypothesized would underlie less extreme inter-individual variations in the plasma LDL cholesterol response to ezetimibe.
Clinical and demographic data
Baseline (mean ± standard deviation) and on-treatment clinical and biochemical attributes
55.6 ± 11.9
54.0 ± 10.7
58.0 ± 13.3
days on treatment
83.8 ± 60.6
90.1 ± 67.6
74.5 ± 47.9
percent on statin
plasma lipids and lipoproteins (mmol/L)
6.57 ± 1.43
6.33 ± 1.54
6.93 ± 1.18
4.51 ± 1.40
4.35 ± 1.53
4.72 ± 1.18
1.18 ± 0.30
1.15 ± 0.29
1.22 ± 0.31
2.50 ± 2.36
2.63 ± 2.86
2.32 ± 1.33
5.41 ± 1.32
5.10 ± 1.21
5.88 ± 1.35
3.35 ± 1.15
3.21 ± 1.11
3.56 ± 1.19
1.23 ± 0.45
1.16 ± 0.33
1.33 ± 0.60
2.25 ± 1.91
2.24 ± 2.12
2.25 ± 1.57
NPC1L1 genotype frequencies
Genetic descriptors of study sample
NPC1L1 haplotype definition and frequencies
Genetic associations with plasma lipoproteins
Clinical and biochemical features according to NPC1L1 haplotype
56.6 ± 13.3
53.9 ± 11.3
58.4 ± 6.9
percent on statin
baseline plasma lipids and lipoproteins (mmol/L)
6.88 ± 1.33
6.31 ± 1.59
6.73 ± 1.01
4.64 ± 1.39
4.41 ± 1.51
4.49 ± 1.10
1.16 ± 0.34
1.19 ± 0.29
1.20 ± 0.21
2.58 ± 1.75
1.99 ± 1.37
3.47 ± 3.78
percent change on-treatment
-16.5 ± 12.2
-15.8 ± 13.0
-22.8 ± 8.4
-23.6 ± 13.2
-23.6 ± 14.7
-35.2 ± 13.5
+10.7 ± 43.0
+1.2 ± 14.3
+0.6 ± 17.0
-4.2 ± 35.6
+2.9 ± 44.9
-0 ± 30.3
An additional post hoc analysis of individual SNPs found that the 11 homozygotes for the 25342C allele had a significantly greater percent reduction in plasma LDL cholesterol from baseline on ezetimibe than did other subjects (P = 0.02). Furthermore, the five homozygotes for the 27677C allele had a significantly greater percent reduction in plasma LDL cholesterol from baseline on ezetimibe than did other subjects (P = 0.013).
In this very preliminary analysis of a small sample of subjects with hypercholesterolemia, we found that genetic variation in NPC1L1, as defined by a three-site SNP haplotype, was significantly associated with inter-individual variation in the response of plasma LDL cholesterol to 12 weeks of treatment with ezetimibe 10 mg daily. Specifically, about one subject in eight did not carry the common NPC1L1 haplotype 1735C-25342A-27677T (designated "haplotype 2"); these subjects were found to have a significantly greater reduction in plasma LDL cholesterol with ezetimibe than subjects with at least one copy of haplotype 2 (-35.9 ± 4.0 versus -23.6 ± 1.6 percent reduction, P = 0.0054). This was paralleled by a similar non-significant trend of between-haplotype differences in reduction of total cholesterol. There were no significant between-haplotype differences in ezetimibe-related changes in plasma triglycerides or HDL cholesterol.
As with many association studies, the present study has limitations , including: 1) a small sample size; 2) no replication sample; 3) no demonstrated functional consequences of the NPC1L1 SNPs or haplotype; 4) no intermediate phenotype, such as cholesterol absorption; and 5) the potential that the positive findings were related to linkage disequilibrium with unmeasured markers at or near the NPC1L1 locus. Also, we did not genotype all SNPs at this locus. However, previous genomic screening experiments  indicated that the remaining SNPs were rare, and thus less likely to add information to the three SNPs studied. Inclusion of these rare SNP genotypes in the extended haplotype would have further subdivided the data into very small-sized cells for statistical analysis.
Our study confirms the similarity of the mean LDL cholesterol response to ezetimibe, namely a 20 to 25% reduction, in various study samples and across a range of demographic features including sex and concomitant statin treatment (6–9). Figure 1 demonstrates that this consistent mean LDL cholesterol reduction occurs on the background of relatively wide inter-individual variation in response. Our findings further indicate that subjects who carry the most common NPC1L1 haplotype (namely haplotype 2), have an ezetimibe-related LDL cholesterol reduction that is within the expected 20 to 25% range. However, a small but substantial group of subjects without haplotype 2 experienced a significantly greater LDL cholesterol reduction, on the order of 35%.
The current finding of NPC1L1-associated inter-individual differences in LDL-cholesterol response to ezetimibe together with our earlier demonstration that rare missense mutations in NPC1L1 are associated with non-response to ezetimibe  support a relationship between this gene product and the mechanism of action of ezetimibe. Clearly, additional mechanistic and genetic studies are required. But these pharmacogenetic results, if confirmed, are consistent with the idea that the NPC1L1 is the ezetimibe target.
Between December 2003 and May 2004, 101 patients with primary hypercholesterolemia (defined as elevated LDL cholesterol) were treated with ezetimibe 10 mg daily according to national dyslipidemia guidelines . Basic demographic attributes of study subjects are shown in Table 1. About one-third of patients were not taking any lipid-lowering medication and the remainder were stable on statin treatment of ≥12 weeks' duration prior to initiation of ezetimibe. Concomitant statin treatment included atorvastatin, rosuvastatin and simvastatin in 30, 28 and 12 subjects, respectively. All subjects provided informed consent and the study was approved by the Ethics Review panel of the University of Western Ontario (review number 07920E).
Biochemical and genetic analyses
The lipoprotein profile after a 12 hour fasting period was determined before initiation of ezetimibe treatment and again after a mean follow-up of 12 weeks. Lipoprotein determinations were performed according to the Ontario Lipoprotein Proficiency Program standards and LDL cholesterol was calculated using the Friedewald-Levy-Fredrickson formula .
Genomic DNA was extracted and three common informative NPC1L1 SNPs from across the coding sequence were chosen for genotyping. Allele-specific genotyping methods were used . For the genotype of exon 2 SNP 1735C>G (trivial name L272L, dbSNP number 2072183), we amplified a 381 bp fragment containing exon 2 using primers 5' GCT CAA CTT CCA GGG AGA CA and 5' AGC TTG TCA GAG AGG CTG G. This was followed by treatment with shrimp alkaline phosphatase (SAP) and Exo I to remove primers and unincorporated dNTPs, followed by ddNTP extension (SnaPShot, PE Applied Biosystems, Mississauga, ON) with primer 5' ATA GGC ATG AGC CAC TGC AC and analysis on a 3730 DNA Sequencer (PE Applied Biosystems, Mississauga, ON). For the genotype of intron 18 SNP 25342A>C, we amplified a 766 bp fragment containing intron 18 using primers 5' GCC CAG GTA GAA GGT GGA GTC and 5' CGT TGT TTG AGA CAT ACA TAG CTG. This was followed by treatment with SAP and Exo I to remove primers and unincorporated dNTPs, gel purification and ddNTP extension with primer 5' CTG CCT GAC ACC TGG CTC TGA and fragment analysis. For the genotype of exon 20 SNP 27677T>C (trivial name V1296V), we amplified the 558 bp fragment containing exon 20 using primers 5' GAA GCT TGG GCT GTG AAC A and 5' CCA CTA TGG GAG CAG AGG AG. This was followed by treatment with SAP and Exo I to remove primers and unincorporated dNTPs, gel purification and ddNTP extension (SnaPShot, PE Applied Biosystems, Mississauga, ON) with primer 5' TCT CTC CGC AGG GCC TGA CGT, and fragment analysis.
Analyses were performed using SAS version 8.2 (Cary, NC), with a nominal level of significance defined as P < 0.05. Significance of the deviation of SNP genotype frequencies from Hardy-Weinberg equilibrium was assessed using chi-square analysis. Pairwise linkage disequilibrium between NPC1L1 alleles was determined using correlation coefficients as described . Three-site maximal likelihood haplotypes were constructed using PHASE version 2.0 . Analysis of variance (ANOVA) was used to identify significant sources of variation for quantitative plasma phenotypes, using F-values computed from type III sums of squares, which is most appropriate for unbalanced study designs. The dependent variables in ANOVA were percent change from baseline of plasma total, LDL and high-density lipoprotein (HDL) cholesterol and triglycerides. The independent variable in ANOVA was NPC1L1 haplotype, with age and sex as covariates within each model.
Supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics, a Career Investigator award from the Heart and Stroke Foundation of Ontario, and operating grants from the Canadian Institutes for Health Research, the Heart and Stroke Foundation of Ontario and the Ontario Research and Development Challenge Fund (Project #0507).
- Davidson MH: Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003, 1: 11-21. 10.1586/14779072.1.1.11View ArticlePubMedGoogle Scholar
- Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004, 303: 1201-1204. 10.1126/science.1093131View ArticlePubMedGoogle Scholar
- Davis HR, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam MH, Lund EG, Detmers PA, Graziano MP, Altmann SW: Niemann-pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole body cholesterol homeostasis. J Biol Chem. 2004, 279: 33586-33592. 10.1074/jbc.M405817200View ArticlePubMedGoogle Scholar
- Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA: Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005, 280: 12710-12720. 10.1074/jbc.M409110200View ArticlePubMedGoogle Scholar
- Iyer SP, Yao X, Crona JH, Hoos LM, Tetzloff G, Davis HR, Graziano MP, Altmann SW: Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochim Biophys Acta. 2005, 1722: 282-292.View ArticlePubMedGoogle Scholar
- Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP, : Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003, 57: 363-368.PubMedGoogle Scholar
- Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony J, Suresh R, Veltri E, : Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004, 58: 746-55. 10.1111/j.1368-5031.2004.00289.xView ArticlePubMedGoogle Scholar
- Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, : Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004, 148: 447-55. 10.1016/j.ahj.2004.03.052View ArticlePubMedGoogle Scholar
- Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005, 80: 587-595.View ArticlePubMedGoogle Scholar
- Wang J, Williams CM, Hegele RA: Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet. 2005, 67: 175-177. 10.1111/j.1399-0004.2004.00388.xView ArticlePubMedGoogle Scholar
- Hegele RA: SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol. 2002, 22: 1058-1061. 10.1161/01.ATV.0000026801.56080.14View ArticlePubMedGoogle Scholar
- Genest J, Frohlich J, Fodor G, McPherson R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J. 2003, 169: 921-924.Google Scholar
- Roberts WC: The Friedewald-Levy-Fredrickson formula for calculating low-density lipoprotein cholesterol, the basis for lipid-lowering therapy. Am J Cardiol. 1988, 62: 345-356. 10.1016/0002-9149(88)90248-2View ArticlePubMedGoogle Scholar
- Hegele RA, Plaetke R, Lalouel JM: Linkage disequilibrium between DNA markers at the low-density lipoprotein receptor gene. Genet Epidemiol. 1990, 7: 69-81. 10.1002/gepi.1370070114View ArticlePubMedGoogle Scholar
- Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003, 73: 1162-1169. 10.1086/379378PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.